- Supernus Pharmaceuticals SUPN +0.08% 87has acquired significant assets from Navitor Pharmaceuticals, enhancing its portfolio in central nervous system treatments.
- The acquisition involves a Phase 2b study and potential milestone payments up to $350 million.
- Supernus Pharmaceuticals demonstrates strong financial health with a robust balance sheet and high institutional ownership.
Supernus Pharmaceuticals (SUPN) has finalized an Asset Purchase Agreement with Navitor Pharmaceuticals, acquiring significant assets related to the compound NV-5138, also known as SPN-820. The detailed agreement includes the transfer of intellectual property rights, inventory, regulatory materials, and associated goodwill from Navitor.
This transaction builds upon prior agreements between the two companies, namely a Development and Option Agreement from April 2020 and a Memorandum of Understanding from May 2025. The purchase price involves Supernus conducting a Phase 2b study and potential milestone payments up to $350 million, dependent on the attainment of specific development, regulatory, and commercial milestones.
Supernus has committed to diligently pursuing these milestones. However, if the Phase 2 study is deemed unsuccessful, the company reserves the right to discontinue further efforts regarding the commercialization of SPN-820.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.